Entries by Justin Slagel

SLA Pharma & KD Pharma Group COVID-19 Clinical Trial Approved

BIOGGIO, SWITZERLAND – April 14, 2020 – The KD Pharma Group (“KD Pharma”) and its partner, SLA Pharma (“SLA”), announced that its new drug candidate EPAspireTM is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. The MHRA in the UK has approved the trial and […]

Meeting with the FDA in October 2019 for ALFA™

SLA Pharma are meeting with the FDA in October 2019 to discuss a new drug application for our late stage development ALFA™ for the treatment of familial adenomatous polyposis (FAP). ALFA™ is currently undergoing clinical studies in Europe, and we are excited that a positive outcome from this FDA meeting will help bring ALFA™ to the […]

SLA Pharma at BIO-Europe 2019

SLA Pharma are attending the annual Bio-Europe conference in Hamburg, Germany from November 11th-13th 2019. The BIO-Europe conference is a great opportunity to meet and connect with hundreds of pharmaceutical companies, one-to-one. SLA Pharma’s CEO, Justin Slagel, looks forward to meeting potential partners, who have an interest in licensing SLA’s late stage assets in gastroenterology. […]